Ghent University Academic Bibliography

Advanced

Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection

Lorena Ibanez UGent, Marina De Filette UGent, Anna Hultberg, Theo Verrips, Nigel Temperton, Robin A Weiss, Wesley Vandevelde, Bert Schepens UGent, Peter Vanlandschoot and Xavier Saelens UGent (2011) JOURNAL OF INFECTIOUS DISEASES. 203(8). p.1063-1072
abstract
Influenza A virus infections impose a recurrent and global disease burden. Current antivirals against influenza are not always effective. We assessed the protective potential of monovalent and bivalent Nanobodies (Ablynx) against challenge with this virus. These Nanobodies were derived from llamas and target H5N1 hemagglutinin. Intranasal administration of Nanobodies effectively controlled homologous influenza A virus replication. Administration of Nanobodies before challenge strongly reduced H5N1 virus replication in the lungs and protected mice from morbidity and mortality after a lethal challenge with H5N1 virus. The bivalent Nanobody was at least 60-fold more effective than the monovalent Nanobody in controlling virus replication. In addition, Nanobody therapy after challenge strongly reduced viral replication and significantly delayed time to death. Epitope mapping revealed that the VHH Nanobody binds to antigenic site B in H5 hemagglutinin. Because Nanobodies are small, stable, and simple to produce, they are a promising, novel therapeutic agent against influenza.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
THERAPY, OSELTAMIVIR, GLYCOPROTEINS, THERAPEUTICS, RECOGNITION, BINDING, HEMAGGLUTININ, HONG-KONG, CHAIN ANTIBODIES, A VIRUSES
journal title
JOURNAL OF INFECTIOUS DISEASES
J. Infect. Dis.
volume
203
issue
8
pages
1063 - 1072
Web of Science type
Article
Web of Science id
000289168500005
JCR category
INFECTIOUS DISEASES
JCR impact factor
6.41 (2011)
JCR rank
3/70 (2011)
JCR quartile
1 (2011)
ISSN
0022-1899
DOI
10.1093/infdis/jiq168
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1212323
handle
http://hdl.handle.net/1854/LU-1212323
date created
2011-04-26 13:53:20
date last changed
2012-06-26 14:32:18
@article{1212323,
  abstract     = {Influenza A virus infections impose a recurrent and global disease burden. Current antivirals against influenza are not always effective. We assessed the protective potential of monovalent and bivalent Nanobodies (Ablynx) against challenge with this virus. These Nanobodies were derived from llamas and target H5N1 hemagglutinin. Intranasal administration of Nanobodies effectively controlled homologous influenza A virus replication. Administration of Nanobodies before challenge strongly reduced H5N1 virus replication in the lungs and protected mice from morbidity and mortality after a lethal challenge with H5N1 virus. The bivalent Nanobody was at least 60-fold more effective than the monovalent Nanobody in controlling virus replication. In addition, Nanobody therapy after challenge strongly reduced viral replication and significantly delayed time to death. Epitope mapping revealed that the VHH Nanobody binds to antigenic site B in H5 hemagglutinin. Because Nanobodies are small, stable, and simple to produce, they are a promising, novel therapeutic agent against influenza.},
  author       = {Ibanez, Lorena and De Filette, Marina and Hultberg, Anna and Verrips, Theo and Temperton, Nigel and Weiss, Robin A and Vandevelde, Wesley and Schepens, Bert and Vanlandschoot, Peter and Saelens, Xavier},
  issn         = {0022-1899},
  journal      = {JOURNAL OF INFECTIOUS DISEASES},
  keyword      = {THERAPY,OSELTAMIVIR,GLYCOPROTEINS,THERAPEUTICS,RECOGNITION,BINDING,HEMAGGLUTININ,HONG-KONG,CHAIN ANTIBODIES,A VIRUSES},
  language     = {eng},
  number       = {8},
  pages        = {1063--1072},
  title        = {Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection},
  url          = {http://dx.doi.org/10.1093/infdis/jiq168},
  volume       = {203},
  year         = {2011},
}

Chicago
Ibanez, Lorena, Marina De Filette, Anna Hultberg, Theo Verrips, Nigel Temperton, Robin A Weiss, Wesley Vandevelde, Bert Schepens, Peter Vanlandschoot, and Xavier Saelens. 2011. “Nanobodies with in Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection.” Journal of Infectious Diseases 203 (8): 1063–1072.
APA
Ibanez, L., De Filette, M., Hultberg, A., Verrips, T., Temperton, N., Weiss, R. A., Vandevelde, W., et al. (2011). Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. JOURNAL OF INFECTIOUS DISEASES, 203(8), 1063–1072.
Vancouver
1.
Ibanez L, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, et al. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. JOURNAL OF INFECTIOUS DISEASES. 2011;203(8):1063–72.
MLA
Ibanez, Lorena, Marina De Filette, Anna Hultberg, et al. “Nanobodies with in Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection.” JOURNAL OF INFECTIOUS DISEASES 203.8 (2011): 1063–1072. Print.